These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 33329600)

  • 1. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.
    Sharma V; Wright KL; Epling-Burnette PK; Reuther GW
    Front Immunol; 2020; 11():604142. PubMed ID: 33329600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.
    McKenney AS; Lau AN; Somasundara AVH; Spitzer B; Intlekofer AM; Ahn J; Shank K; Rapaport FT; Patel MA; Papalexi E; Shih AH; Chiu A; Freinkman E; Akbay EA; Steadman M; Nagaraja R; Yen K; Teruya-Feldstein J; Wong KK; Rampal R; Vander Heiden MG; Thompson CB; Levine RL
    J Clin Invest; 2018 Feb; 128(2):789-804. PubMed ID: 29355841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.
    Zhang SJ; Abdel-Wahab O
    Curr Hematol Malig Rep; 2012 Mar; 7(1):34-42. PubMed ID: 22170482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
    Dunbar A; Nazir A; Levine R
    Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
    Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.
    Meyer SC
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):627-642. PubMed ID: 28673392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
    Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
    Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.
    Fleischman AG; Aichberger KJ; Luty SB; Bumm TG; Petersen CL; Doratotaj S; Vasudevan KB; LaTocha DH; Yang F; Press RD; Loriaux MM; Pahl HL; Silver RT; Agarwal A; O'Hare T; Druker BJ; Bagby GC; Deininger MW
    Blood; 2011 Dec; 118(24):6392-8. PubMed ID: 21860020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?
    Ramos TL; Sánchez-Abarca LI; Redondo A; Hernández-Hernández Á; Almeida AM; Puig N; Rodríguez C; Ortega R; Preciado S; Rico A; Muntión S; Porras JRG; Del Cañizo C; Sánchez-Guijo F
    Oncotarget; 2017 Apr; 8(17):28187-28202. PubMed ID: 28390197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
    O'Sullivan JM; Harrison CN
    Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
    Yin LH; Zheng XQ; Li HY; Bi LX; Shi YF; Ye AF; Wu JB; Gao SM
    Leuk Res; 2015 Apr; 39(4):471-8. PubMed ID: 25666256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms.
    Rao TN; Hansen N; Hilfiker J; Rai S; Majewska JM; Leković D; Gezer D; Andina N; Galli S; Cassel T; Geier F; Delezie J; Nienhold R; Hao-Shen H; Beisel C; Di Palma S; Dimeloe S; Trebicka J; Wolf D; Gassmann M; Fan TW; Lane AN; Handschin C; Dirnhofer S; Kröger N; Hess C; Radimerski T; Koschmieder S; Čokić VP; Skoda RC
    Blood; 2019 Nov; 134(21):1832-1846. PubMed ID: 31511238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK-mutant myeloproliferative neoplasms.
    Levine RL
    Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
    Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic JAK2
    Prestipino A; Emhardt AJ; Aumann K; O'Sullivan D; Gorantla SP; Duquesne S; Melchinger W; Braun L; Vuckovic S; Boerries M; Busch H; Halbach S; Pennisi S; Poggio T; Apostolova P; Veratti P; Hettich M; Niedermann G; Bartholomä M; Shoumariyeh K; Jutzi JS; Wehrle J; Dierks C; Becker H; Schmitt-Graeff A; Follo M; Pfeifer D; Rohr J; Fuchs S; Ehl S; Hartl FA; Minguet S; Miething C; Heidel FH; Kröger N; Triviai I; Brummer T; Finke J; Illert AL; Ruggiero E; Bonini C; Duyster J; Pahl HL; Lane SW; Hill GR; Blazar BR; von Bubnoff N; Pearce EL; Zeiser R
    Sci Transl Med; 2018 Feb; 10(429):. PubMed ID: 29467301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling myeloproliferative neoplasms: From mutations to mouse models and back again.
    Morotti A; Rocca S; Carrà G; Saglio G; Brancaccio M
    Blood Rev; 2017 May; 31(3):139-150. PubMed ID: 27899218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloproliferative neoplasm stem cells.
    Mead AJ; Mullally A
    Blood; 2017 Mar; 129(12):1607-1616. PubMed ID: 28159736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
    Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
    Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
    Bhagwat N; Levine RL; Koppikar P
    Int J Hematol; 2013 Jun; 97(6):695-702. PubMed ID: 23670175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.